11 questions answered from cited research · Plain language
Morning timing of immune checkpoint infusions is linked to better survival in metastatic non-small cell lung cancer, while other new drugs like magrolimab have not shown clear benefits.
Read the full answer →Yes, a phase III trial (CALGB 140503) found sublobar resection noninferior to lobectomy for disease-free survival in small peripheral NSCLC ≤2 cm.
Read the full answer →Bispecific antibodies and CAR T-cell therapy are two immunotherapies being tested for advanced NSCLC; bispecific antibodies show more clinical progress, while CAR T faces challenges like toxicity and tumor trafficking.
Read the full answer →For advanced NSCLC, immunotherapy (especially pembrolizumab) is highly effective for high PD-L1 tumors, while chemotherapy remains a backbone; combining both may improve outcomes.
Read the full answer →High PD-L1 expression (≥50%) often makes immunotherapy, such as pembrolizumab, a first-line option for advanced NSCLC, but other factors like mutations also guide treatment.
Read the full answer →Global disparities in access to new NSCLC therapies stem from differences in drug approval, cost, testing infrastructure, and healthcare system resources.
Read the full answer →In nonsquamous advanced NSCLC, camrelizumab was linked to a higher risk of disease progression and death than pembrolizumab in second-line or later treatment, based on one real-world study.
Read the full answer →Yes, real-world data from over 17,500 patients shows pembrolizumab is effective as first-line treatment for advanced NSCLC with high PD-L1 (≥50%), with median overall survival of 21 months and 29% survival at 5 years.
Read the full answer →Yes, pembrolizumab alone is a standard first-line treatment for advanced NSCLC with PD-L1 ≥50%, with real-world data showing mean overall survival of 21 months and 29% survival at 5 years.
Read the full answer →Yes, Lazcluze (lazertinib) is FDA-approved for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations, in combination with amivantamab.
Read the full answer →Yes, a 2026 meta-analysis found that early-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors, including non-small cell lung cancer.
Read the full answer →